Failure to Diagnose Lung Cancer: A Case-Screening Guide

Cancers are one of the "Big Three" categories of serious diagnostic error, and missed lung cancer is a leading source of malpractice litigation — ranking just behind breast cancer as a cause of claims against radiologists. The recurring failure is not a hidden tumor but a nodule that was on the film — overlooked, misread as benign, or correctly reported but never followed up — while a curable, resectable cancer grew into an incurable one.

Frequency & severity

Lung cancer is the leading cause of cancer death in the United States, and survival is steeply stage-dependent: an early, localized, resectable tumor carries a far better prognosis than a locally advanced or metastatic one. That steep curve is what makes delay so devastating — a missed nodule that would have been a surgically curable Stage I cancer can become a Stage III or IV cancer over the months it goes untracked. Published analyses find the overwhelming majority of missed lung cancers occur on chest radiographs (roughly 90%), with a smaller share on CT, and most are observer-performance errors rather than truly invisible lesions.

The cannot-miss clinical picture & red flags

Lung cancer often has no symptoms until it is advanced, which is precisely why imaging findings — not symptoms — are usually the missed clue. Red flags:

• A pulmonary nodule or mass on a chest x-ray or CT — overlooked, dismissed as benign, or attributed to a vessel, nipple shadow, or old scarring without proper characterization.
• A nodule that was reported but never followed up — the recommendation buried in the report, never communicated to the patient, or never tracked to completion.
• A prior comparison film that shows interval growth — a nodule stable on old imaging is reassuring; a growing one is not, and failure to compare with priors is a classic miss.
• Persistent or unexplained respiratory symptoms — a chronic cough, hemoptysis, recurrent or non-resolving pneumonia, unexplained weight loss, or new hoarseness, especially in a smoker.
• A high-risk patient who was never offered screening — an eligible heavy/former smoker not referred for low-dose CT lung-cancer screening.
• Pneumonia that does not clear on follow-up imaging — an obstructing tumor masquerading as infection, where no repeat film was obtained to confirm resolution.

The dominant standard-of-care framework is nodule follow-up: radiologists generally apply the Fleischner Society guidelines to risk-stratify incidental nodules by size and features and recommend an appropriate surveillance or workup interval. The standard generally requires that the nodule be reported, the recommendation communicated to the ordering clinician and patient, and the follow-up actually completed — and a break in any of those links is a frequent breach.

Dominant allegation types

• Radiology miss — a nodule visible in retrospect that was not reported, misread as benign, or not compared against prior films.
• Failure to follow up a reported nodule — the recommendation was made but never communicated, tracked, or acted on (a loop-closure failure spanning radiology, primary care, and the patient).
• Failure to confirm resolution of pneumonia — an obstructing cancer treated as infection with no repeat imaging.
• Failure to work up red-flag symptoms — hemoptysis, persistent cough, or weight loss in a smoker not imaged or referred.
• Failure to offer eligible patients low-dose CT screening — a high-risk smoker never referred.

What makes a strong vs. weak case

A strong case has a documented finding, a clear failure to act, and a meaningful stage difference:

• Breach: a nodule or finding that was present on imaging and was overlooked, misread, or correctly reported but never followed up — provable with the actual films and reports and, often, a prior comparison study.
• Causation: proof that timely follow-up would more likely than not have caught the cancer when it was smaller and resectable rather than advanced — or, in loss-of-chance jurisdictions, materially improved the chance of cure or survival.
• Damages: more aggressive treatment, reduced survival, recurrence, or death.

A weak or defensible case typically involves a nodule that was genuinely below the threshold for follow-up under the guidelines; an aggressive, fast-doubling tumor where the realistic earlier window would not have changed resectability or outcome; a complete and reasonable workup that simply did not yield the diagnosis; or patient non-adherence — declined or no-showed follow-up imaging, biopsy, or screening. Because lung cancers vary widely in growth rate, the causation analysis must tie the delay interval to the realistic stage at the missed point, and a film-by-film radiology and oncology review is indispensable.

Contributing factors

Recurring factors include observer-performance error on busy chest-radiograph worklists; satisfaction of search (finding one thing and stopping); failure to compare with prior imaging; the burial of follow-up recommendations in long reports that the ordering clinician skims; broken result-tracking across radiology, primary care, and the patient; and the framing of a non-resolving "pneumonia" as infection rather than obstruction. Each can let a resectable cancer advance for months.

The records angle

The chart and imaging archive should establish when the nodule first appeared on any study, exactly how each study was interpreted (and whether priors were compared), whether a follow-up recommendation was made and how it was communicated and tracked, whether the follow-up was completed, and how symptoms and any "pneumonia" were managed. A precise chronology aligning the first imaging clue against the eventual diagnosis defines the delay interval; the serial films, pathology, and staging anchor causation; and the EHR and PACS audit trails confirm when reports were finalized, viewed, and whether anything was amended after diagnosis.

The bottom line

The viable delayed-lung-cancer case usually rests on a nodule that was already on the film — overlooked, misread, or reported but never followed up — while a curable cancer grew. If the imaging shows the finding, the record shows no proper follow-up, and the cancer was one that timely action more likely than not would have caught while resectable, the breach, causation, and damages can all be built from the films, the reports, and the staging data.

General information for attorneys, not legal or medical advice. Standard-of-care, causation, and damages rules vary by jurisdiction — verify every standard, statute, and deadline against current authority in your venue, and rely on a qualified medical expert for the clinical analysis.

Questions? [email protected] · (856) 979-6525